Abiopharma

Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

Oramed and Lifeward Announce Strategic Transaction

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./